LongTerm Safety and Efficacy of ABP 501 in Patients With RA

Long-Term Safety and Efficacy of ABP 501 in Patients With RA

08:00 EDT 31 May 2019 | Medscape

How does the safety and efficacy of the adalimumab biosimilar ABP 501 compare with that of the reference product?
Arthritis Research & Therapy

Original Article: Long-Term Safety and Efficacy of ABP 501 in Patients With RA

More From BioPortfolio on "Long-Term Safety and Efficacy of ABP 501 in Patients With RA"